ceftazidime-avibactam + linezolid

This is a **fixed-dose combination** of **ceftazidime-avibactam** (an antibacterial pairing of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor) with **linezolid** (an oxazolidinone-class antibiotic). - **Ceftazidime** is a β-lactam antibiotic with bactericidal activity against Gram-negative bacteria, mediated by inhibition of cell wall synthesis through binding to penicillin-binding proteins. - **Avibactam** protects ceftazidime from degradation by inhibiting serine β-lactamases (class A, some class C, and some class D), restoring ceftazidime activity against certain resistant bacteria. - **Linezolid** inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, blocking formation of the initiation complex. The combination is not marketed as a single product but may be co-administered for severe multi-drug resistant infections (notably, simultaneous infections due to Gram-negative and Gram-positive pathogens). Development or use is primarily for infections such as complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia, and other situations requiring broad-spectrum empiric therapy, especially involving multi-drug resistant organisms[1][2][3][6][7].